Chargement en cours...
Promoter choice: Who should drive the CAR in T cells?
Chimeric antigen receptor (CAR) T cell therapy is an effective treatment for B cell malignancies, with emerging potential for the treatment of other hematologic cancers and solid tumors. The strength of the promoter within the CAR cassette will alter CAR-polypeptide levels on the cell surface of the...
Enregistré dans:
| Publié dans: | PLoS One |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Public Library of Science
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7380635/ https://ncbi.nlm.nih.gov/pubmed/32706785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0232915 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|